Steven E Lipshultz1, Paige L Williams, Bret Zeldow, James D Wilkinson, Kenneth C Rich, Russell B van Dyke, George R Seage, Laurie B Dooley, Jonathan R Kaltman, George K Siberry, Lynne M Mofenson, William T Shearer, Steven D Colan. 1. aWayne State University School of Medicine and Children's Hospital of Michigan, Detroit, Michigan bUniversity of Miami Leonard M Miller School of Medicine, Miami, Florida cCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts dUniversity of Illinois at Chicago, Chicago, Illinois eTulane University Health Sciences Center, New Orleans, Louisiana fFrontier Science Technology and Research Foundation, Amherst, New York gNational Heart, Lung, and Blood Institute hEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland iBaylor College of Medicine and Texas Children's Hospital, Houston, Texas jBoston Children's Hospital, Boston, Massachusetts, USA.
Abstract
OBJECTIVES: We evaluated the potential cardiac effects of in-utero exposures to antiretroviral drugs in HIV-exposed but uninfected (HEU) children. DESIGN AND METHODS: We compared echocardiographic parameters of left ventricular function (ejection fraction, fractional shortening, and stress-velocity index) and structure (left ventricular dimension, posterior wall/septal thickness, mass, thickness-to-dimension ratio, and wall stress) (expressed as Z-scores to account for age and body surface area) between HEU and HIV-unexposed cohorts from the Pediatric HIV/AIDS Cohort Study's Surveillance Monitoring for ART Toxicities study. Within the HEU group, we investigated the associations between the echocardiographic Z-scores and in-utero exposures to maternal antiretroviral drugs. RESULTS: There were no significant differences in echocardiographic Z-scores between 417 HEU and 98 HIV-unexposed children aged 2-7 years. Restricting the analysis to HEU children, first-trimester exposures to combination antiretroviral therapy (a regimen including at least three antiretroviral drugs) and to certain specific antiretroviral drugs were associated with significantly lower stress-velocity Z-scores (mean decreases of 0.22-0.40 SDs). Exposure to combination antiretroviral therapy was also associated with lower left ventricular dimension Z-scores (mean decrease of 0.44 SD). First-trimester exposure to combination antiretroviral therapy was associated with higher mean left ventricular posterior wall thickness and lower mean left ventricular wall stress Z-scores. CONCLUSION: There was no evidence of significant cardiac toxicity of perinatal combination antiretroviral therapy exposure in HEU children. Subclinical differences in left ventricular structure and function with specific in-utero antiretroviral exposures indicate the need for a longitudinal cardiac study in HEU children to assess long-term cardiac risk and cardiac monitoring recommendations.
OBJECTIVES: We evaluated the potential cardiac effects of in-utero exposures to antiretroviral drugs in HIV-exposed but uninfected (HEU) children. DESIGN AND METHODS: We compared echocardiographic parameters of left ventricular function (ejection fraction, fractional shortening, and stress-velocity index) and structure (left ventricular dimension, posterior wall/septal thickness, mass, thickness-to-dimension ratio, and wall stress) (expressed as Z-scores to account for age and body surface area) between HEU and HIV-unexposed cohorts from the Pediatric HIV/AIDS Cohort Study's Surveillance Monitoring for ART Toxicities study. Within the HEU group, we investigated the associations between the echocardiographic Z-scores and in-utero exposures to maternal antiretroviral drugs. RESULTS: There were no significant differences in echocardiographic Z-scores between 417 HEU and 98 HIV-unexposed children aged 2-7 years. Restricting the analysis to HEUchildren, first-trimester exposures to combination antiretroviral therapy (a regimen including at least three antiretroviral drugs) and to certain specific antiretroviral drugs were associated with significantly lower stress-velocity Z-scores (mean decreases of 0.22-0.40 SDs). Exposure to combination antiretroviral therapy was also associated with lower left ventricular dimension Z-scores (mean decrease of 0.44 SD). First-trimester exposure to combination antiretroviral therapy was associated with higher mean left ventricular posterior wall thickness and lower mean left ventricular wall stress Z-scores. CONCLUSION: There was no evidence of significant cardiac toxicity of perinatal combination antiretroviral therapy exposure in HEUchildren. Subclinical differences in left ventricular structure and function with specific in-utero antiretroviral exposures indicate the need for a longitudinal cardiac study in HEUchildren to assess long-term cardiac risk and cardiac monitoring recommendations.
Authors: Suzanne M Mone; Matthew W Gillman; Tracie L Miller; Eugene H Herman; Steven E Lipshultz Journal: Pediatrics Date: 2004-04 Impact factor: 7.124
Authors: M Gerschenson; S W Erhart; C Y Paik; M C St Claire; K Nagashima; B Skopets; S W Harbaugh; J W Harbaugh; W Quan; M C Poirier Journal: AIDS Res Hum Retroviruses Date: 2000-05-01 Impact factor: 2.205
Authors: Daniel A Duprez; Lewis H Kuller; Russell Tracy; James Otvos; David A Cooper; Jennifer Hoy; Jacqueline Neuhaus; Nicholas I Paton; Nina Friis-Moller; Fiona Lampe; Angelike P Liappis; James D Neaton Journal: Atherosclerosis Date: 2009-05-13 Impact factor: 5.162
Authors: Mariana Gerschenson; Vi Nguyen; Ember L Ewings; Andrea Ceresa; Jaclyn A Shaw; Marisa C St Claire; Kunio Nagashima; Steven W Harbaugh; Jeffrey W Harbaugh; Ofelia A Olivero; Rao L Divi; Paul S Albert; Miriam C Poirier Journal: AIDS Res Hum Retroviruses Date: 2004-01 Impact factor: 2.205
Authors: Jill E Lavigne; William T Shearer; Bruce Thompson; E John Orav; Thomas J Starc; Steven D Colan; Ricardo Pignatelli; Sharon E O'Brien; Louis Bezold; Phillip LaRusa; Kirk A Easley; Irene Cheng; Sarah A Duffy; Steven E Lipshultz Journal: Cardiovasc Toxicol Date: 2004 Impact factor: 3.231
Authors: James D Wilkinson; Paige L Williams; Wendy Yu; Steven D Colan; Armando Mendez; Justin P V Zachariah; Russell B Van Dyke; William T Shearer; Renee E Margossian; Steven E Lipshultz Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: Yongmin Liu; Eunwoo Shim Park; Alexander T Gibbons; Eric D Shide; Rao L Divi; Ruth A Woodward; Miriam C Poirier Journal: Environ Mol Mutagen Date: 2016-07-25 Impact factor: 3.216
Authors: Zaneta D Musimbi; Martin K Rono; James R Otieno; Nelson Kibinge; Lynette Isabella Ochola-Oyier; Etienne Pierre de Villiers; Eunice W Nduati Journal: Sci Rep Date: 2019-12-02 Impact factor: 4.379
Authors: Russell B Van Dyke; Ellen Gould Chadwick; Rohan Hazra; Paige L Williams; George R Seage Journal: Front Immunol Date: 2016-05-23 Impact factor: 7.561
Authors: Nikmah S Idris; Michael M H Cheung; Diederick E Grobbee; David Burgner; Nia Kurniati; Cuno S P M Uiterwaal Journal: PLoS One Date: 2016-01-20 Impact factor: 3.240
Authors: Andrew W McCrary; Winstone M Nyandiko; Alicia M Ellis; Hrishikesh Chakraborty; Michael J Muehlbauer; Myra M Koech; Ibrahim Daud; Elcy Birgen; Nathan M Thielman; Joseph A Kisslo; Piers C A Barker; Gerald S Bloomfield Journal: AIDS Date: 2020-03-15 Impact factor: 4.632